Journal Article

111InIn-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial

Trofimiuk-Müldner, Malgorzata, Mikolajczak, Renata, de Jong, Marion, Virgolini, Irene, Solnica, Bogdan, Nock, Berthold A, Skorkiewicz, Konrad, Fedak, Danuta, Zaletel, Katja, Konijnenberg, Mark, Lezaic, Luka, Decristoforo, Clemens, Gaweda, Paulina, Garnuszek, Piotr, Di Santo, Gianpaolo, Hubalewska-Dydejczyk, Alicja, Przybylik-Mazurek, Elwira, Maina, Theodosia, Erba, Paola Anna, Maecke, Helmut, Kolenc, Petra, Fröberg, Alide C, Rangger, Christine

2023

Overview

IntroductionMedullary thyroid cancer (MTC) is a rare malignant tumour of the parafollicular C-cells with an unpredictable clinical course and currently suboptimal diagnostic and therapeutic options, in particular in advanced disease. Overexpression of cholecystokinin-2 receptors (CCK2R) represents a promising avenue to diagnostic imaging and targeted therapy, ideally through a theranostic approach.Materials and methodsA translational study (GRAN-T-MTC) conducted through a Phase I multicentre clinical trial of the indium-111 labelled CP04 ([111In]In-CP04), a CCK2R-seeking ligand was initiated with the goal of developing a theranostic compound. Patients with proven advanced/metastatic MTC or short calcitonin doubling time were enrolled. A two-step concept was developed through the use of low- and high-peptide mass (10 and 50 μg, respectively) for safety assessment, with the higher peptide mass considered appropriate for therapeutic application. Gelofusine was co-infused in a randomized fashion in the second step for the evaluation of potential reduction of the absorbed dose to the kidneys. Imaging for the purpose of biodistribution, dosimetry evaluation, and diagnostic assessment were performed as well as pre-, peri-, and postprocedural clinical and biochemical assessment.ResultsSixteen patients were enrolled. No serious adverse events after application of the compound at both peptide amounts were witnessed; transient tachycardia and flushing were observed in two patients. No changes in biochemistry and clinical status were observed on follow-up. Preliminary dosimetry assessment revealed the highest dose to urinary bladder, followed by the kidneys and stomach wall. The effective dose for 200 MBq of [111In]In-CP04 was estimated at 7±3 mSv and 7±1 mSv for 10 μg and 50 μg CP04, respectively. Administration of Gelofusine reduced the dose to the kidneys by 53%, resulting in the organ absorbed dose of 0.044±0.019 mSv/MBq. Projected absorbed dose to the kidneys with the use of [177Lu]Lu-CP04 was estimated at 0.9±0.4 Gy/7.4 GBq. [111In]In-CP04 scintigraphy was positive in 13 patients (detection rate of 81%) with superior diagnostic performance over conventional imaging.ConclusionIn the present study, [111In]In-CP04 was shown to be a safe and effective radiopharmaceutical with promising theranostic characteristics for patients with advanced MTC.

• Publisher: Springer Nature B.V
• Subject: Calcitonin / Cancer / Cholecystokinin / Clinical trials / Dosimeters / Dosimetry / Kidneys / Ligands / Medical imaging / Metastases / Metastasis / Peptides / Pharmaceuticals / Radiochemistry / Radioisotopes / Receptors / Scintigraphy / Tachycardia / Thyroid cancer / Tumors / Urinary bladder